Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/μL

Journal of Infectious Diseases

Volumn 182, Issue 4, 2000, Pages 1070-1076

  Jacobson, Mark A ^a,b   Hardy, David ^c   Connick, Elizabeth ^d   Watson, Jessica ^a   DeBruin, Michael ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 12; VIRUS RNA;

ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VERTIGO;

ADULT; CD4 LYMPHOCYTE COUNT; CD8-POSITIVE T-LYMPHOCYTES; CONTINENTAL POPULATION GROUPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MIDDLE AGED; RECOMBINANT PROTEINS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS;

EID: 0033805788     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315819     Document Type: Article

References (29)

1. Interleukin-12 in infectious diseases
2. + T cell counts
3. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro
4. Effects of the Th1 and Th2 stimulatory cytokines interleukin-12 and interleukin-4 on human immunodeficiency virus replication
5. + T cells from human immunodeficiency virus-infected persons
6. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease
7. Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma
8. Controlled trial of interleukin-2 in patients infected with human immunodeficiency virus
9. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: A randomised controlled trial
10. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma
11. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production
12. Phase I study of subcutaneously administered recombinant human interleukin-12 in patients with advanced renal cell cancer
13. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C
14. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B
15. Pilot study of subcutaneous recombinant human interleukin-12 in metastatic melanoma
16. Phase I evaluation of intravenous recombinant human interleukin-12 in patients with advanced malignancies
17. Immunologic effects of interleukin-12 administered by bolus intravenous injection to patients with cancer
18. Effect of interleukin 12 on in vitro HIV type 1 replication depends on clinical stage
19. Interleukin-12 decreases human immunodeficiency virus type 1 replication in human macrophage cultures reconstituted with autologous peripheral blood mononuclear cells
20. Infection of T cell subsets by HIV-1 and the effects of interleukin-12
21. Impaired IL-12 production in human immunodeficiency virus-infected patients
22. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: Effects of interleukin (IL)-12 and anti-IL-10
23. Interleukin-12 enhancement of antigen specific lymphocyte proliferation correlates with stage of human immunodeficiency virus infection
24. Interleukin-12 administered in vivo decreases human NK cell cytotoxicity and antibody-dependent cellular cytotoxicity to human immunodeficiency virus-infected cells
25. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy
26. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens
27. Interleukin-12 enhances antigen-specific proliferation of peripheral blood mononuclear cells from HIV-positive and negative donors in response to Mycobacterium avium
28. Interleukin (IL)-12 deficiency in susceptible mice infected with Mycobacterium avium and amelioration of established infection by IL-12 replacement therapy
29. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source for CC-chemokines and suppress HIV-1 entry and replication in vitro